Topiramate Patent Expiration
Topiramate is Used for preventing migraines in patients 12 years and older. It was first introduced by Janssen Pharmaceuticals Inc
Topiramate Patents
Given below is the list of patents protecting Topiramate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Eprontia | US11433046 | Compositions and methods for treating epilepsy, seizures and other conditions | Aug 21, 2040 | Azurity |
| Eprontia | US11633374 | Compositions and methods for treating epilepsy, seizures and other conditions | Aug 21, 2040 | Azurity |
| Eprontia | US11826343 | Compositions and methods for treating epilepsy, seizures and other conditions | Aug 21, 2040 | Azurity |
| Eprontia | US11911362 | Compositions and methods for treating epilepsy, seizures and other conditions | Aug 21, 2040 | Azurity |
| Eprontia | US12290503 | Compositions and methods for treating epilepsy, seizures and other conditions | Aug 21, 2040 | Azurity |
| Qudexy Xr | US10363224 | Extended-release topiramate capsules | Mar 19, 2033 | Upsher Smith Labs |
| Qudexy Xr | US8652527 | Extended-release topiramate capsules | Mar 19, 2033 | Upsher Smith Labs |
| Qudexy Xr | US8889190 | Extended-release topiramate capsules | Mar 19, 2033 | Upsher Smith Labs |
| Qudexy Xr | US9101545 | Extended-release topiramate capsules | Mar 19, 2033 | Upsher Smith Labs |
| Qudexy Xr | US9555005 | Extended-release topiramate capsules | Mar 19, 2033 | Upsher Smith Labs |
| Trokendi Xr | US8298576 | Sustained-release formulations of topiramate | Apr 04, 2028 | Supernus Pharms |
| Trokendi Xr | US10314790 | Sustained-release formulations of topiramate | Nov 16, 2027 | Supernus Pharms |
| Trokendi Xr | US8298580 | Sustained-release formulations of topiramate | Nov 16, 2027 | Supernus Pharms |
| Trokendi Xr | US8663683 | Sustained-release formulations of topiramate | Nov 16, 2027 | Supernus Pharms |
| Trokendi Xr | US8877248 | Sustained-release formulations of topiramate | Nov 16, 2027 | Supernus Pharms |
| Trokendi Xr | US8889191 | Sustained-release formulations of topiramate | Nov 16, 2027 | Supernus Pharms |
| Trokendi Xr | US8992989 | Sustained-release formulations of topiramate | Nov 16, 2027 | Supernus Pharms |
| Trokendi Xr | US9549940 | Sustained-release formulations of topiramate | Nov 16, 2027 | Supernus Pharms |
| Trokendi Xr | US9555004 | Sustained-release formulations of topiramate | Nov 16, 2027 | Supernus Pharms |
| Trokendi Xr | US9622983 | Sustained-release formulations of topiramate | Nov 16, 2027 | Supernus Pharms |
| Topamax |
US7125560 (Pediatric) | Pharmaceutical composition of topiramate |
Sep 01, 2019
(Expired) | Janssen Pharms |
| Topamax Sprinkle |
US7125560 (Pediatric) | Pharmaceutical composition of topiramate |
Sep 01, 2019
(Expired) | Janssen Pharms |
| Topamax | US7125560 | Pharmaceutical composition of topiramate |
Mar 01, 2019
(Expired) | Janssen Pharms |
| Topamax Sprinkle | US7125560 | Pharmaceutical composition of topiramate |
Mar 01, 2019
(Expired) | Janssen Pharms |
| Topamax |
US5998380 (Pediatric) | Treatment of migraine |
Apr 13, 2016
(Expired) | Janssen Pharms |
| Topamax |
US6503884 (Pediatric) | Migraine treatment method using topiramate and related compounds |
Apr 13, 2016
(Expired) | Janssen Pharms |
| Topamax |
US7018983 (Pediatric) | Treatment of migraine |
Apr 13, 2016
(Expired) | Janssen Pharms |
| Topamax |
US7498311 (Pediatric) | Treatment of migraine |
Apr 13, 2016
(Expired) | Janssen Pharms |
| Topamax Sprinkle |
US5998380 (Pediatric) | Treatment of migraine |
Apr 13, 2016
(Expired) | Janssen Pharms |
| Topamax Sprinkle |
US6503884 (Pediatric) | Migraine treatment method using topiramate and related compounds |
Apr 13, 2016
(Expired) | Janssen Pharms |
| Topamax Sprinkle |
US7018983 (Pediatric) | Treatment of migraine |
Apr 13, 2016
(Expired) | Janssen Pharms |
| Topamax Sprinkle |
US7498311 (Pediatric) | Treatment of migraine |
Apr 13, 2016
(Expired) | Janssen Pharms |
| Topamax | US5998380 | Treatment of migraine |
Oct 13, 2015
(Expired) | Janssen Pharms |
| Topamax | US6503884 | Migraine treatment method using topiramate and related compounds |
Oct 13, 2015
(Expired) | Janssen Pharms |
| Topamax | US7018983 | Treatment of migraine |
Oct 13, 2015
(Expired) | Janssen Pharms |
| Topamax | US7498311 | Treatment of migraine |
Oct 13, 2015
(Expired) | Janssen Pharms |
| Topamax Sprinkle | US5998380 | Treatment of migraine |
Oct 13, 2015
(Expired) | Janssen Pharms |
| Topamax Sprinkle | US6503884 | Migraine treatment method using topiramate and related compounds |
Oct 13, 2015
(Expired) | Janssen Pharms |
| Topamax Sprinkle | US7018983 | Treatment of migraine |
Oct 13, 2015
(Expired) | Janssen Pharms |
| Topamax Sprinkle | US7498311 | Treatment of migraine |
Oct 13, 2015
(Expired) | Janssen Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Topiramate's patents.
Latest Legal Activities on Topiramate's Patents
Given below is the list recent legal activities going on the following patents of Topiramate.
| Activity | Date | Patent Number |
|---|---|---|
| ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2025 | US8652527 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Oct, 2024 | US9622983(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Jul, 2024 | US9555004(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Jul, 2024 | US9555005 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Jul, 2024 | US9549940 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 30 Apr, 2024 | US8298580(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Feb, 2023 | US9101545 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Jan, 2023 | US10363224 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Dec, 2022 | US10314790(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 May, 2022 | US8889190 |
Topiramate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Topiramate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma | St. Jude Children's Research Hospital | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| SMART Use of Medication for the Treatment of Adolescent Severe Obesity | University of Minnesota | NA |
COMPLETED
(Apr 1, 2026)
| PHASE2 |